Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,599.38
(
-0.38%
)
US TECH 100
23,619.61
(
-0.74%
)
Dow Jones
46,022.26
(
-0.44%
)
Brent Oil
107.52
(
0.88%
)
Bitcoin
69,659.52
(
-2.22%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122797
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: spongepaul post# 211353

Tuesday, 05/16/2017 7:04:28 PM

Tuesday, May 16, 2017 7:04:28 PM

Post# of 257259
(CHRS/MNTA/AMGN/etc)—Re: ABBV’s ‘135 Humira patent invalidated

This is bullish for all companies seeking to commercialize Humira FoBs for the US market (as noted in #msg-131355570).

Had ABBV’s ‘135 patent been upheld (or should ABBV prevail on appeal to the CAFC, which is very unlikely, IMO), then Humira-FoB labels would have excluded biweekly subcutaneous dosing to treat RA, which is Humira’s largest single indication.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now